Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays

Dowsett, 2007, International web-based consultation on priorities for translational breast cancer research, Breast Cancer Res, 9, R81, 10.1186/bcr1798

van't Veer, 2005, Gene expression profiling of breast cancer: a new tumor marker, J Clin Oncol, 23, 1631, 10.1200/JCO.2005.12.005

Sotiriou, 2009, Gene-expression signatures in breast cancer, N Engl J Med, 360, 790, 10.1056/NEJMra0801289

Paik, 2004, A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer, N Engl J Med, 351, 2817, 10.1056/NEJMoa041588

Habel, 2006, A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients, Breast Cancer Research, 8, R25, 10.1186/bcr1412

van de Vijver, 2002, A gene-expression signature as a predictor of survival in breast cancer, N Engl J Med, 247, 1999, 10.1056/NEJMoa021967

van't Veer, 2002, Gene expression profiling predicts clinical outcome of breast cancer, Nature, 415, 530, 10.1038/415530a

Sotiriou, 2006, Expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis, J Natl Cancer Inst, 98, 262, 10.1093/jnci/djj052

Ma, 2006, The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer, J Clin Oncol, 24, 4611, 10.1200/JCO.2006.06.6944

Ma, 2008, A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer, Clin Cancer Res, 14, 2601, 10.1158/1078-0432.CCR-07-5026

Wang, 2005, Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer, Lancet, 365, 671, 10.1016/S0140-6736(05)17947-1

Chang, 2005, Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival, Proc Natl Acad Sci USA, 102, 3738, 10.1073/pnas.0409462102

Liu, 2007, The prognostic role of a gene signature from tumorigenic breast-cancer cells, N Engl J Med, 356, 217, 10.1056/NEJMoa063994

Naderi, 2007, A gene-expression signature to predict survival in breast cancer across independent data sets, Oncogene, 26, 1507, 10.1038/sj.onc.1209920

Teschendorff, 2006, A consensus prognostic gene expression classifier for ER positive breast cancer, Genome Biol, 7, R101, 10.1186/gb-2006-7-10-r101

Miller, 2005, An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival, Proc Natl Acad Sci USA, 102, 1350, 10.1073/pnas.0506230102

Glinsky, 2005, Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer, J Clin Invest, 115, 1503, 10.1172/JCI23412

Paik, 2006, Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer, J Clin Oncol, 24, 3726, 10.1200/JCO.2005.04.7985

Goldhirsch, 2007, Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007, Ann Oncol, 18, 1133, 10.1093/annonc/mdm271

Harris, 2007, American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer, J Clin Oncol, 25, 5287, 10.1200/JCO.2007.14.2364

NCCN Practice Guidelines in Oncology. Invasive Breast Cancer. www.NCCN.org, v.2.2008.

Albain, 2007, Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814, INT0100), Breast Cancer Res Treat, 106

Mook, 2008, The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study, Breast Cancer Res Treat

Knauer, 2009, The 70-gene MammaPrint signature is predictive for chemotherapy benefit in early breast cancer, Breast, 18, S36

Castiglione-Gertsch, 2002, Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: A randomized trial of the International Breast Cancer Study Group (Trial IX), J Natl Cancer Inst, 994, 1054

Fisher, 2004, Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings form National Surgical Adjuvant Breast and Bowel Project randomized clinical trials, Lancet, 364, 858, 10.1016/S0140-6736(04)16981-X

Albain, 2005, Concurrent versus sequential chemohormonal therapy versus tamoxifen alone for postmenopausal, node-positive, ER and/or PgR-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (S8814), Breast Cancer Res Treat, 90, 195

2005, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials, Lancet, 365, 1687, 10.1016/S0140-6736(05)66544-0

Buyse, 2006, Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer, J Natl Cancer Inst, 98, 1183, 10.1093/jnci/djj329

Bueno de Mesquita, 2008, Validation of the 70-gene prognosis signature in node-negative breast cancer, Breast Cancer Res Treat

Gianni, 2005, Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer, J Clin Oncol, 23, 7265, 10.1200/JCO.2005.02.0818

Straver, 2009, The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer, Breast Cancer Res Treat

Oratz, 2007, Impact of a commercial reference laboratory test reference laboratory test recurrence score on decision making in early-stage breast cancer, J Oncol Practice, 3, 182, 10.1200/JOP.0742001

Kamal, 2007, How well do standard prognostic criteria predict Oncotype Dx scores?, J Clin Oncol, 25

Lo SS, Mumby PB, Rychlik K, Smerage J, Kash J, Chew HK, et al. Extended followup results from a prospective multi-center study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection, satisfaction and anxiety. J Clin Oncol 2009; in press.

Asad, 2008, Does Oncotype DX recurrence score affect the management of patients with early-stage breast cancer?, Am J Surg, 196, 527, 10.1016/j.amjsurg.2008.06.021

Bueno de Mesquita, 2007, Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a community-based feasibility study (RASTER), Lancet Oncol, 8, 1079, 10.1016/S1470-2045(07)70346-7